Jump to content



Recommended Posts

Immutep (ASX: IMM) are global leaders in the understanding and development of immunotherapy drugs for cancer and autoimmune diseases.


IMM's objective is to harness and strengthen the power of the body's own immune systems through therapeutic intervention for the benefit of patients' health. This is how immunotherapy fights cancer and autoimmune disease.


In this video, the company's CEO Marc Voigt speaks with Share Cafe's Tim McGowen about the company's operations, clinical trials and future developments.




Link to comment
Share on other sites

  • 7 months later...

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

  • Create New...